

**Ref: MHL/Sec&Legal/2024-25/77**

**December 25, 2024**

To,  
**BSE Limited**  
Scrip Code: 542650

**National Stock Exchange of India Ltd.**  
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of Listing Regulations, it is hereby informed that ‘Metropolis Clinical Pathology Private Limited’ has been incorporated as a wholly owned subsidiary of Metropolis Healthcare Limited (‘the Company’) with effect from December 25, 2024.

The details as required under the Listing Regulations are provided in ‘**Annexure A**’ to this intimation.

You are requested to take the above information on record.

Thanking you,  
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni  
Head – Legal & Secretarial

**Encl:** A/a



## Annexure A

(Pursuant to SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023)

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc.	Name: Metropolis Clinical Pathology Private Limited has been formed as a wholly owned subsidiary of the Company.  Turnover: Not applicable.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Metropolis Clinical Pathology Private Limited is a related party of the Company.  The promoter, promoter group / group companies do not have any interest in Metropolis Clinical Pathology Private Limited except to the extent of their shareholding.
Industry to which the entity being acquired belongs	Diagnostic sector.
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Incorporation of a wholly owned subsidiary for undertaking and providing all kinds of diagnostic services.
Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable.
Indicative time period for completion of the acquisition	Not applicable.
Consideration - whether cash consideration or share swap or any other form and details of the same	Initial capital subscription in Cash.
Cost of acquisition and/or the price at which the shares are acquired	Subscription of 10,000 equity shares of face value of INR 10/- each.
Percentage of shareholding / control acquired and / or number of shares acquired	100%
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years’ turnover, country in which the acquired entity has presence and any other significant information (in brief)	Metropolis Clinical Pathology Private Limited is a private company incorporated on December 25, 2024 under the provisions of the Companies Act, 2013, under the CIN: U86905MH2024PTC437094, having its registered office in the State of Maharashtra.  Its main object inter-alia is to undertake and provide all kinds of diagnostic services.

